ENDRA Life Sciences Inc.

Equities

NDRA

US29273B3024

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
0.2525 ^USD	+4.12%		+2.23%	-88.09%

Mar. 28	Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023

December 23, 2022 at 04:12 pm EST

ENDRA Life Sciences Inc. announced that on December 21, 2022, Renaud Maloberti notified the Company of his resignation as the Company's Chief Commercial Officer, effective January 13, 2023. Mr. Maloberti's resignation is not in connection with any disagreement relating to the Company's operations, policies, or practices.

Latest news about ENDRA Life Sciences Inc.

Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
ENDRA Life Sciences Inc. Welcomes the Adoption of the ICD-10 K76.0 Code for the Diagnosis of Non-Alcoholic Fatty Liver Disease	Feb. 21	CI
Transcript : ENDRA Life Sciences Inc., Q3 2023 Earnings Call, Nov 14, 2023	Nov. 14
ENDRA Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
Top Premarket Decliners	23-09-15	MT
Transcript : ENDRA Life Sciences Inc., H1 2023 Earnings Call, Aug 14, 2023	23-08-14
ENDRA Life Sciences Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-14	CI
ENDRA Life Sciences Submits De Novo Request for its TAEUS System Liver Fat Application to the U.S. FDA	23-08-14	CI
Certain Options of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023.	23-07-26	CI
Certain Convertible Preferred Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023.	23-07-26	CI
Certain Warrants of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023.	23-07-26	CI
Certain Common Stock of ENDRA Life Sciences Inc. are subject to a Lock-Up Agreement Ending on 27-JUL-2023.	23-07-26	CI
ENDRA Life Sciences Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Transcript : ENDRA Life Sciences Inc., Q1 2023 Earnings Call, May 15, 2023	23-05-15
ENDRA Life Sciences Prices Public Offering of Shares, Warrants for Net Proceeds of $3.9 Million	23-04-28	MT
US Futures Point Lower Amid Earnings, Ahead of Personal Income, Outlays Report	23-04-28	MT
Top Premarket Decliners	23-04-28	MT
ENDRA Life Sciences Inc. Auditor Raises 'Going Concern' Doubt	23-03-15	CI
Transcript : ENDRA Life Sciences Inc., Q4 2022 Earnings Call, Mar 14, 2023	23-03-14
ENDRA Life Sciences Inc. Announces Resignation of Renaud Maloberti as Chief Commercial Officer, Effective January 13, 2023	22-12-23	CI
ENDRA Life Sciences Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-14	CI
Transcript : ENDRA Life Sciences Inc., Q3 2022 Earnings Call, Nov 14, 2022	22-11-14
Endra Life Sciences Says de Novo Application for TAEUS Monitor Due in 'Coming Weeks'	22-09-29	MT
ENDRA Life Sciences Inc. Plans to Submit De Novo Request to U.S. FDA for Its TAEUS System	22-09-29	CI

Chart ENDRA Life Sciences Inc.

Duration

Period

More charts

Company Profile

ENDRA Life Sciences Inc. is developing an enhanced ultrasound technology platform - Thermo Acoustic Enhanced Ultrasound (TAEUS), a technology which characterizes tissue similar to a magnetic resonance imaging (MRI). The Company's TAEUS technology uses radio frequency (RF) pulses to stimulate tissues, using a small fraction (less than 1%) of the amount of energy that would be transmitted into the body during an MRI scan. The use of RF energy allows its TAEUS technology to penetrate deep into tissue, enabling the imaging of human anatomy at depths equivalent to those of conventional ultrasound. The RF pulses are absorbed by tissue and converted into ultrasound signals. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor steatotic liver disease (SLD), a chronic liver disease spectrum. It is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - German Diabetes Society Meeting

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.2525 USD

Average target price

11 USD

Spread / Average Target

+4,256.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENDRA LIFE SCIENCES INC.	-88.09%	2.79M
IQVIA HOLDINGS INC.	+1.51%	42.75B
LONZA GROUP AG	+48.15%	41.61B
MODERNA, INC.	+8.57%	41.34B
CELLTRION, INC.	-12.36%	26.59B
ICON PUBLIC LIMITED COMPANY	+8.92%	25.49B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.12B
MEDPACE HOLDINGS, INC.	+29.17%	12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.35%	11B

Other Biotechnology & Medical Research